Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With Metronomic VEX in Advanced Triple-negative Breast Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Vinorelbine
Related studies linked through entity extraction aliases.
Trotabresib in Combination With Vinorelbine and Radiation Therapy for the Treatment of HER2+ Breast Cancer With Central Nervous System or Leptomeningeal Metastasis
- Status
- WITHDRAWN
- Phase
- PHASE1
Organoid-based Functional Precision Therapy for Advanced Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE3
Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease
- Status
- RECRUITING
- Phase
- PHASE2
A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Inetetamab Combined With Pyrotinib and Vinorelbine as First-line to Third-line Treatment for HER2-positive Metastatic Breast Cancer
- Status
- UNKNOWN
- Phase
- N/A
A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in Treating Relapsed/Refractory Classical Hodgkin Lymphoma
- Status
- WITHDRAWN
- Phase
- PHASE3
Vinorelbine Metronomic Chemotherapy Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of Advanced Refractory Non-small Cell Lung Cancer and Breast Cancer(PRaG 6.0)
- Status
- UNKNOWN
- Phase
- PHASE2
Efficacy and Safety of the Combination of Trastuzumab Plus TUCAtinib Plus viNorelbine in Patients With HER2-positive Non-resectable Locally Advanced or Metastatic Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE2
SMMART Adaptive Clinical Treatment (ACT) Trial
- Status
- WITHDRAWN
- Phase
- EARLY_PHASE1
A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Pyrotinib and Vinorelbine Tartrate Capsules With or Without Inetetamab for First Line Treatment in Patients With Trastuzumab-resistant HER2-positive Advanced Breast Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA)
- Status
- WITHDRAWN
- Phase
- PHASE3
Pyrotinib Maleate Combined With Vinorelbine in the Treatment of HER2-positive Advanced Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Guided Treatment Based on Mini-PDX in Metastatic Triple Negative Breast Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer
- Status
- COMPLETED
- Phase
- PHASE3
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2